Anti-CD19 [PDR134]

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti-CD19 [PDR134]
• Alternate name: CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; CVID3; B4
• Research fields: Cancer;Cell signaling and signal transduction;Immunology;Stem cell biology
• Clone: PDR134
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Reactivity: Human
• Host: Mouse
• Application: FACS ; IHC ; IF ; IP ; WB
• Description: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by progenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic lymphocytic leukemia and non-Hodgkin’s lymphoma). Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.
• Immunogen: Pokeweek-stimulated Daudi and Raji cells
• Isotype: IgM
• Myeloma used: P3/NS1/1-Ag4.1

Target Details

• Target: CD19
• Target background: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by progenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic lymphocytic leukemia and non-Hodgkin's lymphoma). Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.

Applications

• Application: FACS ; IHC ; IF ; IP ; WB

Handling

• Format: Liquid
• Concentration: 1 mg/ml
• Unit size: 100 ug
• Storage buffer: PBS with 0.02% azide
• Storage conditions: -15° C to -25° C
• Shipping conditions: Dry ice

References

• Sato S and Tedder TF. 1997. CD19 Workshop Panel report. In Kishimoto T, et al (eds) Leucocyte Typing VI, Garland Publishing Inc., New York and London, p 133-135
• Tedder TF et al. 1995. B-cell antigens: section report. In Schlossman SF, et al (eds) Leucocyte Typing V, Vol 1, Oxford University Press, Oxford, New York and Tokyo, p 491.